Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475553 · ClinicalTrials.gov registry record · NA
Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®
A NA study of Breakthrough Bleeding and Breakthrough Spotting, sponsored by Scott and White Hospital & Clinic.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00475553: Completed NA study of Breakthrough Bleeding and Breakthrough Spotting, sponsored by Scott and White Hospital & Clinic.
NCT00475553 is a NA study of Breakthrough Bleeding and Breakthrough Spotting that has completed, run by Scott and White Hospital & Clinic. The registered enrollment target is 75 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00475553, a NA study of Breakthrough Bleeding and Breakthrough Spotting, has completed, sponsored by Scott and White Hospital & Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate the best way to manage breakthrough spotting and bleeding during an extended use regimen of NuvaRing®. Ease of use and acceptability of a flexible regimen of NuvaRing® will also be evaluated. A comparison of cyclic mood symptoms, pelvic pain, and headaches will be made between a standard 21/7 regimen and an extended regimen.
Conditions Studied
Interventions
- OTHER remove ring if bleeding or spotting occurs more than 5 days
- OTHER If bleeding does not remove ring
Study Locations (1)
Texas
- Scott & White Hospital and Clinic - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-05 |
| Phase | NA |
What the finished NCT00475553 record still lists
NCT00475553 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Breakthrough Bleeding appearing as the primary indexed condition, and to 2 interventions - of which remove ring if bleeding or spotting occurs more than 5 days is the first listed.
NCT00475553 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00475553 about?
NCT00475553 is a clinical study titled "Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®". The purpose of this research study is to evaluate the best way to manage breakthrough spotting and bleeding during an extended use regimen of NuvaRing®. Ease of use and acceptability of a flexible regimen of NuvaRing® will also be evaluated. A comparison of cyclic mood symptoms, pelvic pain, and hea...
What is the current status of trial NCT00475553?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2006-05. Estimated completion is 2008-05.
What conditions does trial NCT00475553 study?
This clinical trial studies the following conditions: Breakthrough Bleeding, Breakthrough Spotting.
What interventions are being tested in trial NCT00475553?
The interventions under investigation include: remove ring if bleeding or spotting occurs more than 5 days (OTHER), If bleeding does not remove ring (OTHER).
Who is sponsoring clinical trial NCT00475553?
This trial is sponsored by Scott and White Hospital & Clinic, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00475553 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breakthrough Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00475553's enrollment target sits among peer trials
75 1069th of 2000 higher than 919 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia